Patents by Inventor Somasekhar Bhamidipati

Somasekhar Bhamidipati has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME
    Publication number: 20240368119
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Application
    Filed: March 29, 2024
    Publication date: November 7, 2024
    Inventors: Yan CHEN, Jiaxin YU, Simon SHAW, Ihab DARWISH, Vanessa TAYLOR, Somasekhar BHAMIDIPATI, Zhushou LUO, Rao KOLLURI
  • RIP1 inhibitory compounds and methods for making and using the same
    Patent number: 12116354
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Grant
    Filed: September 7, 2022
    Date of Patent: October 15, 2024
    Assignee: RIGEL PHARMACEUTICALS, INC.
    Inventors: Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
  • PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS
    Publication number: 20230399326
    Abstract: Disclosed herein are embodiments of a pyrazole compound according to formula I. Compositions comprising the compound, and a method for making the composition also are disclosed. The composition may comprise a carrier, such as a polymer and/or the composition may be a spray-dried formulation. Also disclosed is a method for using the compound and/or composition. The compound and/or composition may be useful to inhibit an IRAK protein and/or to ameliorate, treat and/or prevent an IRAK-associated disease or condition in a subject.
    Type: Application
    Filed: August 24, 2023
    Publication date: December 14, 2023
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Lu Chou, Matt Duan, Ihab S. Darwish, Simon Shaw, Somasekhar Bhamidipati, Vanessa Taylor, Yan Chen, Dazhong Fan, Zhushou Luo
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 11827628
    Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
    Type: Grant
    Filed: November 2, 2021
    Date of Patent: November 28, 2023
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Sambaiah Thota, David Carroll, Ankush Argade, Kin Tso, Arvinder Sran, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Vanessa Taylor, Robin Cooper, Rajinder Singh, Brian Wong
  • RIP1 Inhibitory Compounds and Methods for Making and Using the Same
    Publication number: 20230322732
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Application
    Filed: June 14, 2023
    Publication date: October 12, 2023
    Inventors: Somasekhar BHAMIDIPATI, Vanessa TAYLOR
  • RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME
    Publication number: 20230310454
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Application
    Filed: December 6, 2022
    Publication date: October 5, 2023
    Inventors: Jiaxin YU, Ihab DARWISH, Vanessa TAYLOR, Rao KOLLURI, Yan CHEN, Simon SHAW, Somasekhar BHAMIDIPATI, Zhushou LUO
  • RIP1K INHIBITORS
    Publication number: 20230265100
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Application
    Filed: April 26, 2023
    Publication date: August 24, 2023
    Inventors: Somasekhar BHAMIDIPATI, Simon SHAW, Ihab DARWISH, Jiaxin YU, Rao KOLLURI, Vanessa TAYLOR, Esteban MASUDA, Mark IRVING
  • Tyrosine kinase inhibitors
    Patent number: 11672791
    Abstract: Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.
    Type: Grant
    Filed: September 2, 2021
    Date of Patent: June 13, 2023
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Sacha Holland, Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Rao Kolluri, Ihab Darwish, Esteban Masuda, Jiaxin Yu
  • RIP1K inhibitors
    Patent number: 11667643
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: June 6, 2023
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Somasekhar Bhamidipati, Simon Shaw, Ihab Darwish, Jiaxin Yu, Rao Kolluri, Vanessa Taylor, Esteban Masuda, Mark Irving
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 11667611
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: June 6, 2023
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ankush Argade, Arvinder Sran, David Carroll, Jeffrey Clough, Kin Tso, Somasekhar Bhamidipati, Sambaiah Thota, Rajinder Singh, Vanessa Taylor, Hui Li, Esteban Masuda
  • HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS
    Publication number: 20230143161
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The compounds may have a structure according to Formula I The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Application
    Filed: December 16, 2022
    Publication date: May 11, 2023
    Inventors: Yan CHEN, Jiaxin YU, Simon SHAW, Ihab DARWISH, Vanessa TAYLOR, Somasekhar BHAMIDIPATI, Zhushou LUO, Rao KOLLURI
  • TGF-ß INHIBITORS
    Publication number: 20230123591
    Abstract: Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, X, Z, m, p, and R2 are as described herein. In certain embodiments, a compound disclosed herein inhibits the activity of one or more members of the TGF-? superfamily, and can be used to treat disease by blocking such activity.
    Type: Application
    Filed: October 7, 2022
    Publication date: April 20, 2023
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Marina Gelman, Todd Kinsella, Somasekhar Bhamidipati, Ihab Darwish, Rajinder Singh, Jiaxin Yu
  • RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME
    Publication number: 20230112865
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Application
    Filed: June 17, 2022
    Publication date: April 13, 2023
    Inventors: Yan CHEN, Jiaxin YU, Simon SHAW, Ihab DARWISH, Vanessa TAYLOR, Somasekhar BHAMIDIPATI, Zhushou LUO, Rao KOLLURI
  • RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME
    Publication number: 20230113841
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Application
    Filed: September 7, 2022
    Publication date: April 13, 2023
    Inventors: Esteban MASUDA, Simon SHAW, Vanessa TAYLOR, Somasekhar BHAMIDIPATI
  • HETEROCYCLIC RIP1 KINASE INHIBITORS
    Publication number: 20230057341
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Application
    Filed: September 16, 2022
    Publication date: February 23, 2023
    Inventors: Simon SHAW, Somasekhar BHAMIDIPATI, Vanessa TAYLOR
  • Heterocyclic RIP1 inhibitory compounds
    Patent number: 11578078
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The compounds may have a structure according to Formula I The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: February 14, 2023
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Yan Chen, Jiaxin Yu, Simon Shaw, Ihab Darwish, Vanessa Taylor, Somasekhar Bhamidipati, Zhushou Luo, Rao Kolluri
  • RIP1 inhibitory compounds and methods for making and using the same
    Patent number: 11564930
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: January 31, 2023
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Jiaxin Yu, Ihab Darwish, Vanessa Taylor, Rao Kolluri, Yan Chen, Simon Shaw, Somasekhar Bhamidipati, Zhushou Luo
  • TYROSINE KINASE INHIBITORS
    Publication number: 20230012676
    Abstract: Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.
    Type: Application
    Filed: September 2, 2021
    Publication date: January 19, 2023
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Sacha Holland, Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Rao Kolluri, Ihab Darwish, Esteban Masuda, Jiaxin Yu
  • Heterocyclic RIP1 kinase inhibitors
    Patent number: 11479543
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: October 25, 2022
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Simon Shaw, Somasekhar Bhamidipati, Vanessa Taylor
  • RIP1 inhibitory compounds and methods for making and using the same
    Patent number: 11472782
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: October 18, 2022
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati